H.C. Wainwright raised the firm’s price target on Cadrenal Therapeutics (CVKD) to $32 from $3 and keeps a Buy rating on the shares following the 1-for-15 reverse stock split.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVKD:
Questions or Comments about the article? Write to editor@tipranks.com